There's some new blood at the helm of London-based drug giant GlaxoSmithKline's venture group. Jens Eckstein, previously a venture partner and entrepreneur-in-residence at TVM Capital, has jumped aboard as president of SR One. He takes over for biotech venture capitalist Christoph Westphal, who had been wearing multiple hats. Westphal ran the show at SR One while serving as a partner of his own VC group, Longwood Founders Fund, which has funding support from GSK, Genzyme and other sources. Eckstein, a biochemist by training, was a general partner focused on early stage life sciences investments before his role changed to venture partner and EIR earlier this year. Release